Sino Biopharmaceutical Limited has announced that its self-developed Class 1 innovative drug, TDI01 suspension, a "ROCK2 inhibitor," has been included in the Breakthrough Therapy Designation process by the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration of China. This designation is for the treatment of moderate to severe chronic graft-versus-host disease (cGVHD) in patients who have undergone at least one but no more than five prior lines of systemic therapy. TDI01 is an innovative, oral, and highly selective ROCK2 inhibitor, marking it as the first of its kind domestically developed in China. The company aims to provide more innovative and effective treatment options for patients through this development. The announcement highlights Sino Biopharmaceutical Limited's commitment to advancing healthcare solutions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.